ALGOTX
European biotech AlgoTx, the developer of first-in-class treatment ATX01 for chemotherapy-induced peripheral neuropathy (CIPN), announced today the success of a €20M Series B fundraising led by Relyens Innovation Santé / Turenne Capital , followed by UI Investissement, and historical investors Bpifrance through its Innobio 2 fund and Omnes Capital. Early and new business angel investors also significantly participated in this financing round, and AlgoTx secured an additional 1M€ in non-dilutive financing. The proceeds will be used to demonstrate the clinical efficacy of ATX01 in neuropathic pain.
Bervin Bouani, Investment Director at Turenne Capital, commented: “We are very proud to lead this strategic financing round to support AlgoTx to continue the clinical development of ATX01 lead candidate that has the potential to significantly improve the lives of patients with neuropathic pain. We look forward to working with Stéphane and his outstanding team to transform AlgoTx into a global pain player.”
Following the demonstration of ATX01’s early clinical safety and low systemic passage in Phase 1, the Phase 2 “ACT” study will now assess ATX01’s ability to reduce pain in adult CIPN patients – a program granted “fast-track” designation by FDA. In parallel, the Phase 2 “EASE” study will explore ATX01’s efficacy in the debilitating pain of erythromelalgia, a program for which ATX01 was granted “Orphan Disease Designation” in the US and Europe.
Stéphane Thiroloix, Founder & CEO of AlgoTx, says: “It is incredibly exciting to start the efficacy trials of ATX01, supported by such a high-profile syndicate of investors. We look forward to enrolling patients in our studies any day now.”
Over half of cancer patients treated with chemotherapy develop CIPN and experience sensory symptoms and pain in the hands and feet: loss of sensitivity, tingling, burning, cold and intense pain can persist for months to years after treatment. It affects over two million patients in the US and Europe and represents a leading cause for modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists, neurologists and pain specialists.
« We are very pleased to support the AlgoTx team in the development of ATX01, driven by our belief in its significant impact in the treatment of CIPN and other neuropathic pain. AlgoTx can truly transform the lives of patients suffering from these conditions », says Pauline de Breteuil Senior Partner UI Investissement / FCPI Majycc Innovation Santé.
About AlgoTx
AlgoTx develops novel treatments for complex pain, with lead program ATX01 in Phase 2 in chemotherapy-induced peripheral neuropathy (NCT05593614) and erythromelalgia. More information at www.algotx.com
ACT study : ATX01 for the pain of ChemoTherapy, (NCT05593614). EASE study : Efficacy of ATX01 / Study in Erythromelalgia.
ABOUT TURENNE GROUP/RELYENS INNOVATION SANTÉ
Launched in 2014, Relyens Innovation Santé is is an evergreen venture capital vehicle specializing in health innovation controlled and owned by Relyens, a mutual insurance company specializing in the risk management of health, social and medical players. Relyens is the leading French player in medical civil liability. Advised by Turenne Santé (Health Division of Turenne Group), Relyens Innovation Santé's mission is to support the growth and development phases of innovative companies in the health sector.
Turenne Group, one of the leading private equity companies in France, has been supporting entrepreneurs for 23 years in their company’s innovation, development and transfer projects. As an independent player, the Group has assets of €1.4 billion under management. Its teams, made up of 68 professionals, including 52 investors, based in Paris, Lille (Nord Capital Partenaires), Lyon, Bordeaux, Marseille, Nice and Metz, support 290 business leaders, particularly in the healthcare, hospitality, innovation, BtoB services, and in the digital and impact sectors. With more than €300m, our healthcare team (Turenne Santé) invests across the entire value creation chain for healthcare companies through various investment approaches.
For more information: www.relyens.eu/fr / www.turennecapital.com
About Bpifrance and InnoBio 2
Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export).
InnoBio 2 is an investment fund dedicated to life sciences, managed by Bpifrance, which is also one of the LPs alongside Sanofi, Boehringer Ingelheim, Takeda, Ipsen, Servier, BMS, European Investment Fund and Pasteur Mutualité. InnoBio 2, with €203 million, aims to invest in companies developing innovative products and services, close to or in early clinical development, with the objective of bringing them until the clinical proof of concept. InnoBio 2 takes minority equity stake in companies and can lead or co-lead the investment rounds.
For more information, please visit: www.bpifrance.com – Follow us on Twitter : @bpifrance - @BpifrancePresse
About Omnes
Omnes is a leading Paris-based European investor in private equity and infrastructure. With more than €5 billion in assets under management, Omnes provides companies with the equity capital they need to grow through its four core businesses: Venture Capital, Buyout & Growth Capital, Infrastructure and Co-Investment. With more than 30 trade sales and nearly 15 IPOs in 20 years (including Themis Bioscience, Biovex, arGEN-X, Novaled and Direct Energie), Omnes Venture Capital team is a leading French player in financing innovative SMEs with dual expertise in the deep-tech and healthcare sectors. Omnes is committed to ESG issues and has set up the Omnes Foundation in aid of children’s charities. The company is also a signatory to the United Nations Principles for Responsible Investment (PRI). www.omnescapital.com
About UI Investissement
UI Investissement is an independent, specialized company in the development of unlisted French companies with €1.5 billion under management. For over 50 years, UI Investissement has been committed to work alongside the managers of growing SMEs and STIs to help them emerge as economically and sustainably successful businesses through its focus on three areas: health, agro-business, and business services.
With its expertise, UI Investissement provides support to companies in the health sector at all stages of their development and plays a central role in the ecosystem. It is through the Majycc Innovation Santé fund that UI Investissement supports entrepreneurs who aim to be the architects of tomorrow's health. The roots of Majycc Innovation Santé are deeply connected to the DNA of several private clinic groups, nursing home groups, and mutual health insurance companies, representing entrepreneurship, health and human values, respect for corporate culture, and the projects of the individuals who build them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005169/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Tech Services Market Hits New High in Q4, on Strong AI, Cloud, Managed Services Demand: ISG Index™19.1.2026 10:00:00 CET | Press release
Combined market ACV up 27%, to record US $10.9 billionManaged services ACV up 19%, while XaaS soars 34% Demand for technology services in Europe reached a new high in the fourth quarter as the region turned in its best quarterly performance of the year to close out 2025, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows fourth-quarter ACV for the combined market (both managed services and cloud-based as-a-service) advanced 27 percent, to a record US $10.9 billion. It was the region’s eighth consecutive quarter of combined market growth, averaging 16 percent in that span. “Europe saved its best for last, with accelerating, AI-fueled demand for cloud services, coupled with renewed momentum in managed services, leading the region to its strong
Celonis Champions “Free the Process” Movement at WEF Davos 202619.1.2026 10:00:00 CET | Press release
Process Intelligence leader to demonstrate why open ecosystems and open data access are critical to bridge the gap between AI hype and economic impact Celonis, a global leader in Process Intelligence - a key enabler of enterprise AI, today announced its participation in the World Economic Forum (WEF) Annual Meeting 2026. Under the event’s theme “A Spirit of Dialogue,” Celonis leaders — including Co-founder and Co-CEO Bastian Nominacher and President Carsten Thoma — will outline what’s needed to make the critical shift from AI experimentation to responsible AI implementation and meaningful RoAI (Return on AI Investment). In an AI-driven world, processes are the engine of enterprise value, and process intelligence is the essential foundation for AI, giving it the cross-system context needed to drive real growth. At WEF 2026, Celonis will outline how an open ecosystem enables organizations to "Free the Process" from rigid systems and vendor-locked silos, so that teams can collaborate, com
Posiflex to Showcase AI-Powered Retail Innovation at EuroShop 202619.1.2026 09:57:00 CET | Press release
From AI-powered self-checkout to next-generation Tap-to-Pay transactions, Posiflex presents end-to-end solutions that redefine the modern retail journey Posiflex Technology, Inc., a global leader in Point of Sale (POS) systems and Online-to-Offline (O2O) solutions, will present its latest portfolio of AI-powered retail innovations at EuroShop 2026, taking place from February 22 to 26, 2026 at Messe Düsseldorf, Germany. Celebrating the 60th edition of the world’s leading retail trade fair, Posiflex will demonstrate how AI-enabled technologies and scenario-driven system design can address the evolving demands of modern retail environments, spanning self-checkout, AI recognition, contactless transactions, kitchen operations, and next-generation self-service. Visitors are invited to explore these solutions at Hall 6, Booth C42, and discover how Posiflex supports retailers in building agile, future-ready business models. This press release features multimedia. View the full release here: ht
Alta Semper Signs Definitive Agreements to Acquire a Majority Stake in Nature’s Rule, a MENA-Focused Leader in Dietary Supplements and Sports Nutrition19.1.2026 09:13:00 CET | Press release
Alta Semper, a London-based private equity firm focused on healthcare and consumer investments across growth markets, today announced that it has signed definitive agreements to acquire a majority stake in Nature’s Rule, a leading sports nutrition and dietary supplements company headquartered in the UAE, with an established manufacturing presence in Egypt. The acquisition is a majority investment in Prowell Holding, the parent company of Nature’s Rule, the operator of the largest fully dedicated sports nutrition and dietary supplements manufacturing facility in MENA. The company’s infrastructure and in-house R&D capabilities support a portfolio of private-label clients and proprietary brands, including Redrex, its flagship, market-leading sports nutrition brand developed in collaboration with global bodybuilding icon Mamdouh Elssbiay (“Big Ramy”). The founders will retain a significant stake and continue to lead the business. The partnership will execute a focused value-creation plan t
The UK Chooses Bridge Over Troubled Water as the Nation’s Favourite Song of Hope in Solidarity With Refugees19.1.2026 09:00:00 CET | Press release
Simon and Garfunkel classic named the UK’s top #HopeHitOver 1000 people from across the country nominated songs to show their solidarity with refugees around the world this winterThe most popular Hope Hits available on the Hope On Repeat playlist to get you through Blue Monday Simon and Garfunkel’s Bridge Over Troubled Water has been votedas the UK’s number one #HopeHit ― as part of UK for UNHCR’s ‘Hope on Repeat’ campaign, raising awareness of the hardships facing refugees across the globe this winter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119165712/en/ Simon & Garfunkel's Bridge Over Troubled Water voted the UK's number one #HopeHit With 10% of the public vote, Bridge Over Troubled Water emerged as the UK’s most popular #HopeHit. Since November, the UN Refugee Agency’s national charity partner has invited people to nominate their #HopeHits - the tunes that connect us and warm our hearts as the weather gets cold
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom